A citation-based method for searching scientific literature


List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
42

Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
Shinsuke Nirengi, Carmem Peres Valgas da Silva, Kristin I Stanford. Curr Opin Pharmacol 2020
6
33

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass,[...]. Circulation 2021
62
28

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Jens Aberle, Markus Menzen, Sebastian M Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F Scheerer, John Xu, Weifeng Tang, Andreas L Birkenfeld. Sci Rep 2020
7
28

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
265
28

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
328
28

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
Thomas M Maddox, James L Januzzi, Larry A Allen, Khadijah Breathett, Javed Butler, Leslie L Davis, Gregg C Fonarow, Nasrien E Ibrahim, JoAnn Lindenfeld, Frederick A Masoudi,[...]. J Am Coll Cardiol 2021
189
28

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
174
28

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
28

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Erik J M van Bommel, Frank Geurts, Marcel H A Muskiet, Adrian Post, Stephan J L Bakker, A H Jan Danser, Daan J Touw, Miranda van Berkel, Mark H H Kramer, Max Nieuwdorp,[...]. Clin Sci (Lond) 2020
4
50

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
28

Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Subodh Verma, Qiuhe Ji, Deepak L Bhatt, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Isabella Zwiener, Jyothis T George,[...]. Diabetes Obes Metab 2020
12
28

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
155
28

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
95
28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
28

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.
Valeriya Lyssenko, Roberto Lupi, Piero Marchetti, Silvia Del Guerra, Marju Orho-Melander, Peter Almgren, Marketa Sjögren, Charlotte Ling, Karl-Fredrik Eriksson, Asa-Linda Lethagen,[...]. J Clin Invest 2007
535
14

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
667
14

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
715
14

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Paola Dongiovanni, Salvatore Petta, Cristina Maglio, Anna Ludovica Fracanzani, Rosaria Pipitone, Enrico Mozzi, Benedetta Maria Motta, Dorota Kaminska, Raffaela Rametta, Stefania Grimaudo,[...]. Hepatology 2015
299
14


Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.
Hashem B El-Serag, Michael L Johnson, Christine Hachem, Robert O Morgana. Gastroenterology 2009
202
14

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Kento Imajo, Takaomi Kessoku, Yasushi Honda, Wataru Tomeno, Yuji Ogawa, Hironori Mawatari, Koji Fujita, Masato Yoneda, Masataka Taguri, Hideyuki Hyogo,[...]. Gastroenterology 2016
390
14

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fernando Bril, Michael J McPhaul, Michael P Caulfield, Jean-Marie Castille, Thierry Poynard, Consuelo Soldevila-Pico, Virginia C Clark, Roberto J Firpi-Morell, Jinping Lai, Kenneth Cusi. J Investig Med 2019
25
14

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lee-Lee Lai, Shireene Ratna Vethakkan, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Wah-Kheong Chan. Dig Dis Sci 2020
54
14

17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Yanling Ma, Olga V Belyaeva, Philip M Brown, Koji Fujita, Katherine Valles, Suman Karki, Ynto S de Boer, Christopher Koh, Yanhua Chen, Xiaomeng Du,[...]. Hepatology 2019
116
14

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
Tran Thi Khanh Tuong, Dang Khoa Tran, Pham Quang Thien Phu, Tong Nguyen Diem Hong, Thien Chu Dinh, Dinh Toi Chu. Diagnostics (Basel) 2020
14
14

Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Eduardo Vilar-Gomez, Raj Vuppalanchi, Archita P Desai, Samer Gawrieh, Marwan Ghabril, Romil Saxena, Oscar W Cummings, Naga Chalasani. Aliment Pharmacol Ther 2019
26
14

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
248
14

Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes.
Federica Zatterale, Michele Longo, Jamal Naderi, Gregory Alexander Raciti, Antonella Desiderio, Claudia Miele, Francesco Beguinot. Front Physiol 2020
190
14

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
Ming-Feng Xia, Huan-Dong Lin, Ling-Yan Chen, Li Wu, Hui Ma, Qian Li, Qiqige Aleteng, Yu Hu, Wan-Yuan He, Jian Gao,[...]. Diabetologia 2019
16
14

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
Temitope Foster, Matthew J Budoff, Sammy Saab, Naser Ahmadi, Craig Gordon, Alan D Guerci. Am J Gastroenterol 2011
176
14


Intrahepatic Fat and Postprandial Glycemia Increase After Consumption of a Diet Enriched in Saturated Fat Compared With Free Sugars.
Siôn A Parry, Fredrik Rosqvist, Ferenc E Mozes, Thomas Cornfield, Matthew Hutchinson, Marie-Eve Piche, Andreas J Hülsmeier, Thorsten Hornemann, Pamela Dyson, Leanne Hodson. Diabetes Care 2020
13
14

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
432
14

Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans.
Kasper W Ter Horst, Pim W Gilijamse, Ruth I Versteeg, Mariette T Ackermans, Aart J Nederveen, Susanne E la Fleur, Johannes A Romijn, Max Nieuwdorp, Dongyan Zhang, Varman T Samuel,[...]. Cell Rep 2017
83
14

Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher, Paola Loria. Expert Rev Gastroenterol Hepatol 2015
56
14

Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.
Max C Petersen, Gerald I Shulman. Trends Pharmacol Sci 2017
161
14

Glucose and Lipid Dysmetabolism in a Rat Model of Prediabetes Induced by a High-Sucrose Diet.
Ana Burgeiro, Manuela G Cerqueira, Bárbara M Varela-Rodríguez, Sara Nunes, Paula Neto, Frederico C Pereira, Flávio Reis, Eugénia Carvalho. Nutrients 2017
24
14

Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogenic enzymes by modifying nutrient sensing factors in rats.
Alba Rebollo, Núria Roglans, Miguel Baena, Anna Padrosa, Rosa M Sánchez, Manuel Merlos, Marta Alegret, Juan C Laguna. J Nutr Biochem 2014
28
14

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji,[...]. Lancet Gastroenterol Hepatol 2019
245
14

Targeting endoplasmic reticulum stress in insulin resistance.
Laia Salvadó, Xavier Palomer, Emma Barroso, Manuel Vázquez-Carrera. Trends Endocrinol Metab 2015
125
14

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Mohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, Raj Vuppalanchi, Brent A Neuschwander-Tetri, James Tonascia, Cynthia Guy, Rohit Loomba, Srinivasan Dasarathy, Julia Wattacheril,[...]. J Hepatol 2020
45
14

Metabolic Inflammation and Insulin Resistance in Obesity.
Huaizhu Wu, Christie M Ballantyne. Circ Res 2020
98
14

Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue.
Anneleen Remmerie, Liesbet Martens, Charlotte L Scott. Front Endocrinol (Lausanne) 2020
15
14

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
Stergios A Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S Mantzoros. Metabolism 2020
44
14

NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
14

Non-alcoholic fatty liver disease.
James Maurice, Pinelopi Manousou. Clin Med (Lond) 2018
55
14


Medical liver biopsy: background, indications, procedure and histopathology.
Alexander Boyd, Owen Cain, Abhishek Chauhan, Gwilym James Webb. Frontline Gastroenterol 2020
19
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.